CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 17 enrolled
Drug / intervention
MK-2060 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05769595
NCT05769595Phase 1Completed
CompareCT.gov

A Single-dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-2060 in Japanese Older Participants With End-stage Renal Disease on Dialysis.

Merck Sharp & Dohme LLC·interventional·Posted Mar 15, 2023·Updated Mar 14, 2025

In Brief

A Phase 1 clinical trial evaluating MK-2060 and Placebo for End-Stage Renal Disease (ESRD) and 2 related conditions. Completed, enrolled 17 participants across 12 sites.

Detailed Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of MK-2060 after a single dose intravenous (IV) administration in Japanese older participants with end stage renal disease (ESRD) on dialysis. There is no primary hypothesis for this study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnd-Stage Renal Disease (ESRD), End-Stage Kidney Disease (ESKD), Kidney Failure, Chronic
CountriesJapan
Collaborators--

Timeline

Phase 1CompletedFinished
202420252026
First PostedMar 15, 2023
Enrollment StartJun 14, 2023
Primary CompletionFeb 15, 2024
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 3.3 years ago

Interventions

MK-2060biological

Lyophilized powder diluted in normal saline for IV infusion

Placebodrug

IV infusion